The impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma

Susanne Smolka; Julius Chapiro; Wilfred Manzano; John Treilhard; Eric Reiner; Yanhong Deng; Yan Zhao; Bernd Hamm; James S Duncan; Bernhard Gebauer; MingDe Lin; Jean-François Geschwind

doi:10.1016/j.clinimag.2017.05.007

The impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma

Clin Imaging. 2017 Nov-Dec:46:1-7. doi: 10.1016/j.clinimag.2017.05.007. Epub 2017 Jun 7.

Authors

Affiliations

¹ Radiologie, Charité Universitätsmediz in Berlin, Augustenburger Platz 1, 13353 Berlin, Germany; Yale School of Medicine, Department of Radiology and Biomedical Imaging, 333 Cedar Street, New Haven, CT 06520, USA.
² Yale School of Medicine, Department of Radiology and Biomedical Imaging, 333 Cedar Street, New Haven, CT 06520, USA.
³ University of California, UC Irvine School of Medicine, 252 Irvine Hall, 1001 Health Sciences Road, Irvine, CA 92697-3950, USA.
⁴ Yale School of Engineering & Applied Science, Department of Biomedical Engineering, 300 Cedar Street, New Haven, CT 06519, USA.
⁵ Yale School of Public Health, Yale Center for Analytic Sciences, 300 George Street, Suite 555, New Haven, CT 06520, USA.
⁶ Fourth Military Medical University of China, No. 169, Changle West Road, Xi'an, Shaanxi, 710032, China.
⁷ Radiologie, Charité Universitätsmediz in Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
⁸ Philips Research North America, 2 Canal Park, 3rd Floor, Cambridge, MA 02141, USA.
⁹ Yale School of Medicine, Department of Radiology and Biomedical Imaging, 333 Cedar Street, New Haven, CT 06520, USA. Electronic address: jeff.geschwind@yale.edu.

Abstract

Purpose: To investigate whether bevacizumab compromises early response assessment after Transarterial Chemoembolization (TACE) in patients with hepatocellular carcinoma by 3D quantitative European Association for the Study of the Liver (qEASL) criteria in comparison to other imaging-based criteria.

Materials and methods: Each of 14 patients receiving TACE and bevacizumab was matched with two patients receiving TACE alone. Baseline and Follow-up MRI was retrospectively analyzed regarding qEASL and other imaging-based criteria.

Results: Percentage-based qEASL achieved significant separation in both therapy arms (p=0.046 and p=0.015). Response and Overall Survival showed similar association among treatment groups (p=0.749).

Conclusions: Anti-angiogenic therapy with bevacizumab does not impede early response assessment by qEASL.

Keywords: Antiangiogenic agents; Bevacizumab; HCC; Quantitative imaging; TACE; qEASL.

Publication types

Comparative Study

MeSH terms

Adult
Aged
Aged, 80 and over
Angiogenesis Inhibitors / therapeutic use*
Bevacizumab / therapeutic use*
Carcinoma, Hepatocellular / drug therapy
Carcinoma, Hepatocellular / pathology*
Carcinoma, Hepatocellular / therapy
Chemoembolization, Therapeutic*
Female
Humans
Liver / pathology*
Liver Neoplasms / drug therapy
Liver Neoplasms / pathology*
Liver Neoplasms / therapy
Magnetic Resonance Imaging / methods
Male
Middle Aged
Retrospective Studies
Treatment Outcome
Vascular Surgical Procedures

Substances

Angiogenesis Inhibitors
Bevacizumab

Abstract

Publication types

MeSH terms

Substances

Grants and funding